Filtros de búsqueda

Lista de obras de Jean-Charles Soria

10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient

artículo científico publicado en 2015

19q13-ERCC1 gene copy number increase in non--small-cell lung cancer

artículo científico publicado en 2013

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

artículo científico publicado en 2016

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.

artículo científico publicado en 2016

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study

artículo científico publicado en 2016

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

artículo científico publicado en 2017

A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma

artículo científico publicado en 2012

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

artículo científico publicado en 2011

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

artículo científico publicado en 2013

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib

artículo científico publicado en 2016

A novel antibody-based approach to detect the functional ERCC1-202 isoform.

artículo científico publicado en 2018

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

artículo científico publicado en 2007

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors

artículo científico publicado en 2016

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

artículo científico publicado en 2013

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

artículo científico publicado en 2013

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

artículo científico publicado en 2010

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

artículo científico publicado en 2014

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2016

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced

artículo científico publicado en 2017

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours

artículo científico publicado en 2014

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

artículo científico publicado en 2017

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

artículo científico publicado en 2015

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development

artículo científico publicado en 2012

Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers

artículo científico publicado en 2002

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

artículo científico publicado en 2015

Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis

artículo científico publicado en 2001

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

artículo científico publicado en 2009

Added value of molecular targeted agents in oncology

artículo científico publicado en 2011

Adjuvant chemotherapy and radiotherapy in non-small cell lung cancer

artículo científico publicado en 2004

Adjuvant chemotherapy in early-stage non-small cell lung cancer

artículo científico publicado en 2005

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

artículo científico

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

artículo científico publicado en 2011

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

artículo científico publicado en 2016

Antiangiogenic agents and late anastomotic complications

artículo científico publicado en 2010

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

artículo científico publicado en 2015

Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth

artículo científico publicado en 2006

Aquaporin expression in human lymphocytes and dendritic cells

artículo científico

Are RAS mutations predictive markers of resistance to standard chemotherapy?

artículo científico publicado en 2009

Are phase I trials safe for older patients?

artículo científico publicado en 2017

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).

artículo científico publicado en 2016

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

artículo científico publicado en 2016

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

artículo científico publicado en 2015

Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer ⬇️

artículo científico publicado el 16 de octubre de 2003

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation

artículo científico publicado en 2010

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

artículo científico publicado en 2017

Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells

artículo científico publicado en 2011

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung

artículo científico publicado en 2016

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

artículo científico publicado en 2007

Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists ⬇️

artículo científico publicado el 16 de febrero de 2011

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials

artículo científico publicado en 2016

Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.

artículo científico publicado en 2007

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

artículo científico publicado en 2015

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

artículo científico publicado en 2015

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients

artículo científico publicado en 2017

Circulating tumor cells in lung cancer

artículo científico publicado en 2012

Cisplatin resistance associated with PARP hyperactivation

artículo científico publicado en 2013

Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.

artículo científico publicado en 2015

Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development

artículo científico publicado en 2008

Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours

artículo científico publicado en 2006

Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial

artículo científico publicado en 2016

Controversies and challenges regarding the impact of radiation therapy on survival

artículo científico

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

artículo científico publicado en 2018

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.

artículo científico publicado en 2015

Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.

artículo científico publicado en 2016

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

artículo científico publicado en 2016

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

artículo científico publicado en 2011

Cutaneous side-effects of kinase inhibitors and blocking antibodies

artículo científico publicado en 2005

Cyclooxygenase 2 inhibitors and cancer chemoprevention

artículo científico publicado en 2004

Cyclooxygenase-2 as a target for anticancer drug development

artículo científico publicado en 2006

DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer.

artículo científico publicado en 2010

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

artículo científico publicado en 2006

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

artículo científico publicado en 2018

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

artículo científico publicado en 2014

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

artículo científico publicado en 2015

Dendritic cell-derived exosomes for cancer therapy

artículo científico publicado en 2016

Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination

artículo científico publicado en 2010

Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients

artículo científico publicado en 2004

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer

artículo científico publicado en 2013

Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma

artículo científico publicado en 2015

Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

artículo científico publicado en 2011

Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL.

artículo científico publicado en 2011

Differential expression of biomarkers in men and women

artículo científico publicado en 2009

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites

artículo científico publicado en 2009

Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours

artículo científico publicado en 2004

Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.

artículo científico publicado en 2007

Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers

artículo científico

Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

artículo científico publicado en 2001

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

artículo científico publicado en 2014

Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials

artículo científico publicado en 2011

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

artículo científico publicado en 2008

Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies

artículo científico publicado en 2013

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer

artículo científico publicado en 2014

Dysphonia induced by anti-angiogenic compounds

artículo científico

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

artículo científico publicado en 2015

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

artículo científico publicado en 2011

EGFR-targeted therapies: what's new?

artículo científico publicado en 2006

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis

artículo científico publicado en 2010

ERCC1 and RRM1: ready for prime time?

artículo científico publicado en 2013

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer

artículo científico publicado en 2007

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform

artículo científico publicado en 2013

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

artículo científico publicado en 2013

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

artículo científico publicado en 2009

Electrolyte disorders related to EGFR-targeting drugs

scientific article published on 28 April 2009

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

artículo científico publicado en 2016

Environmental, genetic, and molecular features of prostate cancer

artículo científico publicado en 2004

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives

artículo científico publicado en 2005

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

artículo científico publicado en 2017

Europe does it better: molecular testing across a national health care system-the French example

artículo científico

Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs

artículo científico publicado en 2012

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

artículo científico publicado en 2017

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

artículo científico publicado en 2012

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy

artículo científico publicado en 2014

Expanding role of chemotherapy in lung cancer

artículo científico publicado en 2006

Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer

artículo científico publicado en 2008

Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers.

artículo científico publicado en 2009

Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer

artículo científico publicado en 2006

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

artículo científico publicado en 2016

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives

artículo científico

First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation

artículo científico publicado en 2015

First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient

artículo científico publicado en 2013

First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas.

artículo científico publicado en 2016

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

artículo científico publicado en 2017

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

artículo científico publicado en 2012

From theoretical synergy to clinical supra-additive toxicity

artículo científico publicado en 2009

Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy

artículo científico publicado en 2005

Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer

artículo científico

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

artículo científico publicado en 2015

Gene expression profiling of non-small-cell lung cancer

artículo científico publicado en 2008

Genomes in the clinic: the Gustave Roussy Cancer Center experience

artículo científico publicado en 2014

Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors

artículo científico publicado en 2014

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour

artículo científico publicado en 2009

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

artículo científico publicado en 2015

Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data

artículo científico publicado en 2009

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

artículo científico publicado en 2016

IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype

artículo científico publicado en 2009

IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy

artículo científico publicado en 2013

Imatinib in small cell lung cancer

artículo científico publicado en 2003

Immune checkpoint inhibitors in advanced nonsmall cell lung cancer

artículo científico publicado en 2015

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

artículo científico publicado en 2018

Immune-checkpoints: the new anti-cancer immunotherapies

artículo científico publicado en 2013

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

artículo científico publicado en 2016

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.

artículo científico publicado en 2011

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

artículo científico publicado en 2018

Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology

artículo científico publicado en 2014

Implementing precision medicine initiatives in the clinic: a new paradigm in drug development

artículo científico publicado en 2014

Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.

artículo científico publicado en 2017

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

artículo científico publicado en 2017

Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being?

artículo científico publicado en 2013

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC

artículo científico publicado en 2014

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

artículo científico publicado en 2017

Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response

artículo científico publicado el 1 de octubre de 2010

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

artículo científico publicado en 2012

Involvement of aquaporins in colorectal carcinogenesis

artículo científico

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

artículo científico publicado en 2009

Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center

artículo científico publicado en 2014

LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer.

artículo científico publicado en 2014

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value

artículo científico publicado en 2017

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation

artículo científico publicado en 2002

Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer

artículo científico

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer

artículo científico publicado en 2017

Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma

artículo científico publicado en 2008

Loss of PTEN expression as a prognostic marker for tongue cancer

artículo científico

Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC.

artículo científico publicado en 2003

Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer

artículo científico publicado en 2012

Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?

artículo científico

MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer

artículo científico publicado en 2016

MVP and vinorelbine for malignant pleural mesothelioma

artículo científico publicado en 2008

Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view

artículo científico publicado en 2012

Management of hypertension in angiogenesis inhibitor-treated patients

scientific article published on 15 January 2009

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

artículo científico publicado en 2015

Management of non-small-cell lung cancer: recent developments

artículo científico

Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers

artículo científico publicado en 2008

Membrane trafficking of AQP5 and cAMP dependent phosphorylation in bronchial epithelium

artículo científico publicado en 2007

Method for semi-automated microscopy of filtration-enriched circulating tumor cells

artículo científico publicado en 2016

Minimal residual disease in solid neoplasia: New frontier or red-herring?

artículo científico publicado en 2011

Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers

artículo científico publicado en 2008

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients

artículo científico publicado en 2013

Modifying phase I methodology to facilitate enrolment of molecularly selected patients

artículo científico publicado en 2013

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.

artículo científico publicado en 2011

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial

artículo científico publicado en 2017

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

scientific article published on 15 June 2010

Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas

artículo científico publicado en 2005

Molecular screening for a personalized treatment approach in advanced adrenocortical cancer

artículo científico publicado en 2013

Molecular targeting: targeting angiogenesis in solid tumors

artículo científico publicado en 2004

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.

artículo científico publicado en 2016

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

artículo científico publicado en 2010

MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer

artículo científico publicado en 2010

Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas

artículo científico publicado en 2013

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

artículo científico publicado en 2016

NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors

artículo científico publicado en 2005

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2010

New concepts for phase I trials: evaluating new drugs combined with radiation therapy

artículo científico publicado en 2005

New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge

artículo científico publicado en 2017

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer

artículo científico publicado en 2013

No evidence for viral sequences in five lepidic adenocarcinomas (former "BAC") by a high-throughput sequencing approach

artículo científico publicado en 2015

Nonapoptotic role for Apaf-1 in the DNA damage checkpoint

artículo científico publicado en 2007

Novel therapeutic targets in advanced urothelial carcinoma

artículo científico publicado en 2015

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

artículo científico publicado en 2013

Osimertinib in EGFR Mutation–Positive Advanced NSCLC.

artículo científico publicado en 2018

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2017

Otorhinolaryngological Toxicities of New Drugs in Oncology

artículo científico publicado en 2017

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

artículo científico publicado en 2017

Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication

artículo científico publicado en 2000

P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy

artículo científico publicado en 2016

PARP inhibitors: an interesting pathway also for non-small cell lung cancer?

artículo científico publicado en 2014

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs

artículo científico publicado en 2013

PI3K-AKT-mTOR pathway inhibitors

artículo científico publicado en 2006

PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology.

artículo científico publicado en 2016

PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology

artículo científico publicado en 2016

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

artículo científico publicado en 2012

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience

artículo científico publicado en 2015

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

artículo científico publicado en 2017

Pemetrexed-induced pneumonitis: a case report

artículo científico publicado en 2009

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

artículo científico

Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?

artículo científico publicado en 2014

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

artículo científico publicado en 2010

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

artículo científico publicado en 2013

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

artículo científico publicado en 2009

Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer

artículo científico publicado en 2011

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

artículo científico publicado en 2015

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

artículo científico publicado en 2017

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies

artículo científico publicado en 2015

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab ⬇️

artículo científico publicado el 25 de octubre de 2010

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

artículo científico publicado en 2016

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.

artículo científico publicado en 2014

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

artículo científico publicado en 2013

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

artículo científico publicado en 2013

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

artículo científico publicado en 2017

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors

artículo científico publicado en 2017

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

artículo científico publicado en 2017

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors

artículo científico publicado en 2015

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors

artículo científico publicado en 2016

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas

artículo científico publicado en 2016

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

artículo científico publicado en 2014

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

artículo científico publicado en 2018

Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.

artículo científico publicado en 2013

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

artículo científico publicado en 2012

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

artículo científico publicado en 2015

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

artículo científico publicado en 2013

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

artículo científico publicado en 2012

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

artículo científico publicado en 2013

Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients

artículo científico publicado en 2016

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

artículo científico publicado en 2017

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

artículo científico publicado en 2007

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

artículo científico publicado en 2000

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

artículo científico publicado en 2013

Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer

artículo científico publicado en 2010

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

artículo científico publicado en 2017

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy

artículo científico publicado en 2013

Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway

artículo científico publicado en 2008

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial

artículo científico publicado en 2017

Predicting response to Iressa: unexpected mechanism

artículo científico publicado en 2004

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

artículo científico publicado en 2012

Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study

artículo científico publicado en 2010

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

artículo científico publicado en 2017

Prioritizing targets for precision cancer medicine

artículo científico publicado en 2014

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

artículo científico publicado en 2016

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

artículo científico publicado en 2017

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients

artículo científico publicado en 2017

Prognostic value of LIPC in non-small cell lung carcinoma

artículo científico publicado en 2013

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

artículo científico publicado en 2017

Protein kinases C: a new cytoplasmic target

artículo científico publicado en 2008

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report

artículo científico publicado en 2009

QT interval prolongation among patients treated with angiogenesis inhibitors

scientific article published on April 2009

Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism

artículo científico publicado en 2013

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study

artículo científico publicado en 2017

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

artículo científico publicado en 2014

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

artículo científico publicado en 2011

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy

artículo científico publicado en 2016

Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer

artículo científico publicado en 2012

Rationale for anti-OX40 cancer immunotherapy

artículo científico publicado en 2015

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials

artículo científico publicado en 2011

Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations

artículo científico publicado en 2006

Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers

artículo científico publicado en 2003

Reversible cardiogenic shock following 5-fluorouracil infusion.

artículo científico publicado en 2009

Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor

artículo científico publicado en 2010

Rociletinib in EGFR-mutated non-small-cell lung cancer

artículo científico publicado en 2015

Role of human aquaporin 5 in colorectal carcinogenesis

artículo científico

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

artículo científico publicado en 2016

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

artículo científico publicado en 2006

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

artículo científico publicado en 2017

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

artículo científico publicado en 2015

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

artículo científico publicado en 2018

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies

artículo científico publicado en 2008

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

artículo científico publicado en 2016

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease

artículo científico publicado en 2012

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease

artículo científico publicado en 2007

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

artículo científico publicado en 2010

Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.

artículo científico publicado en 2014

Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.

artículo científico publicado en 2013

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

artículo científico publicado en 2015

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

artículo científico publicado en 2017

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

artículo científico

Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient

artículo científico publicado en 2017

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

artículo científico publicado en 2013

Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines

artículo científico publicado en 2009

Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival

artículo científico

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2012

Targeted molecular therapy: the example of Iressa (ZD1839)

artículo científico publicado en 2003

Targeted therapies in lung cancer.

artículo científico publicado en 2007

Targeted therapy-induced radiation recall

artículo científico publicado en 2013

Targeting FGFR Signaling in Cancer

artículo científico

Targeting angiogenesis with oral agents

artículo científico publicado en 2006

Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives

artículo científico publicado en 2007

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

artículo científico publicado en 2016

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

artículo científico publicado en 2018

Telomerase expression in lung preneoplasia and neoplasia

artículo científico publicado en 2007

Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases

artículo científico publicado en 2008

Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process

artículo científico publicado en 2008

Telomere maintenance and DNA damage responses during lung carcinogenesis.

artículo científico publicado en 2010

Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects

artículo científico

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

artículo científico publicado en 2017

The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 15 de noviembre de 2010

The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma

artículo científico publicado en 2009

The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy ⬇️

artículo científico

The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials

scientific article published on 07 August 2008

The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?

artículo científico publicado en 2014

The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer

artículo científico publicado en 2015

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

artículo científico publicado en 2012

The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer

scientific article published on March 2010

Therapeutic implications of epidermal growth factor receptor in lung cancer

artículo científico publicado en 2003

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

artículo científico publicado en 2014

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study

artículo científico publicado en 2010

Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

artículo científico publicado en 2017

Translating metastasis-related biomarkers to the clinic--progress and pitfalls

artículo científico

Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance

artículo científico publicado en 2016

Tumor assessment criteria in phase I trials: beyond RECIST.

artículo científico publicado en 2012

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data

artículo científico publicado en 2013

Tumour molecular profiling for deciding therapy-the French initiative

artículo científico publicado en 2012

Tumour stem cell-targeted treatment: elimination or differentiation

artículo científico publicado en 2006

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.

artículo científico publicado en 2010

Update to Rociletinib Data with the RECIST Confirmed Response Rate

artículo científico publicado en 2016

Use of angiogenesis inhibitors in tumour treatment

artículo científico publicado en 2005

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

artículo científico publicado en 2009

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

artículo científico publicado en 2015

Vascular disrupting agents: a delicate balance between efficacy and side effects

artículo científico

What can be done for patients with NSCLC without druggable targets?

artículo científico publicado en 2013

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients

artículo científico publicado en 2017

Wound healing delay after central venous access following DCF/VEGF-trap therapy.

artículo científico publicado en 2009

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].

artículo científico publicado en 2015

[Discrepancies between primary tumor and metastasis: impact on personalized medicine].

artículo científico publicado en 2013

[Epidermal growth factor receptor and chemoprevention of epithelial tumor: rationale and development methods].

artículo científico publicado en 2003

[Expression of chemokine receptors by cancer cells].

artículo científico publicado en 2004

[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].

artículo científico publicado en 2012

[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].

artículo científico publicado en 2015

p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients

artículo científico publicado en 2012

rCGH: a comprehensive array-based genomic profile platform for precision medicine

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda